34 results about "Brown Adipocyte" patented technology

In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

The present invention addresses the problem of providing: a brown adipocyte; a method for preparing the brown adipocyte; a transplantation material containing a brown adipocyte; a prophylactic or therapeutic agent for various diseases and conditions, which contains a brown adipocyte; and a use. As a means for solving the problem, a method for preparing a brown adipocyte is provided, said method being characterized by comprising culturing a differentiated somatic cell from a mammal in a culture medium in the presence of at least one compound selected from the group consisting of (1) a TGFbeta / SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) an MEK / ERK pathway inhibitor to convert the somatic cell into a brown adipocyte.

The invention discloses a preparation method of a brown adipocyte product, and the brown adipocyte product obtained by adopting the corresponding preparation method can promote osteogenic differentiation of BMSC, reduce the number of osteoclasts, reduce the gene expression level related to osteoclast differentiation, increase the volume fraction and thickness of cortical bones and cancellous bones. The product can be used for preparing medicines for preventing and treating osteoporosis.

The invention discloses an application of a brown adipocyte-derived exosome. The invention discloses application of the brown adipocyte-derived exosome in preparation of a medicine for treating non-alcoholic fatty liver, and preferably application in preparation of a medicine for treating non-alcoholic fatty liver caused by high fat obesity. The brown adipocyte-derived exosome is used for expressing symbolic proteins CD63, CD9 and TSG101. The extracted brown adipocyte-derived exosome can effectively reduce the weight of non-alcoholic fatty liver of high-fat-induced obese mice and the ratio of liver to volume, reduce the content of fatty acid and cholesterol in the liver, reduce the liver, slow down fat synthesis in the liver and increase the consumption of fatty acid at the same time. Therefore the invention provides a new way for treating non-alcoholic fatty liver of obese mice caused by high fat.

A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.

The invention relates to a new application of a compound Compound C, which is the application of the compound Compound C in the preparation of a medicament for promoting the expression of adipocyte UCP1. The browning of adipocytes is promoted, that is, the expression of brown adipocytes marker gene uncoupling protein 1 (UCP1) is enhanced, excess fat can be effectively consumed in the form of calories, glucose uptake and fatty acid oxidation can be promoted, the number and vitality of mitochondria can be improved, and the levels of glucose and lipid metabolism and energy metabolism in the bodycan be enhanced, thereby effectively treating fatty liver, impaired glucose tolerance, insulin resistance and type 2 diabetes. Therefore, the compound Compound C has an effect of promoting the expression of the adipocyte UCP1, and can effectively prevent and treat the fatty liver, the impaired glucose tolerance, the insulin resistanceand the type 2 diabetes.

The present invention provides an application of a thermogenesis-enhancing compound to enhance the thermogenesis induced by a norepinephrine compound in brown adipocytes. Specifically, the present invention provides a use of a thermogenesis-enhancing compound for preparing a preparation or a composition. The preparation or composition is used to enhance the heat production efficiency of brown fat cells induced by NE compounds, wherein the heat production enhancing compound is selected from the group consisting of ATP compounds, ATP synthase inhibitors, or combinations thereof. The heat production enhancing compound of the present invention can significantly enhance the heat production efficiency of brown fat cells induced by norepinephrine compounds.

The application of butylenephthalide (butylidenephthalide, BP) includes using butylenephthalide (BP) to provide a kind of kit for promoting the differentiation of stem cells into brown adipocytes, and using butylenephthalide (BP) in the manufacture of A use of a medicament, wherein the medicament is used for inhibiting the accumulation of white fat, promoting the transformation of white fat into brown fat, inhibiting weight gain and / or reducing the content of triglyceride, glucose and total cholesterol in blood.

Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

Provided is a composition that comprises a supernatant of brown adipocytes or a purified product thereof and has a metabolism improving effect. Also provided is a method for preparing the aforesaid supernatant without using a liquid culture containing glucose at a high concentration. Also provided is a method for producing brown adipocytes using pluripotent stem cells, said method being useful for preparing a supernatant of brown adipocytes. In the present invention, a supernatant having a metabolism improving effect was successfully obtained from brown adipocytes. Also, this supernatant could be obtained without using a liquid culture containing glucose at a high concentration. In the present invention, moreover, brown adipocytes were successfully formed from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail, etc. The supernatant of brown adipocytes according to the present invention is expected as applicable to the development of therapeutic drugs for sugar metabolism-related diseases and cosmetics.

The invention discloses a composition for reducing body fat rate and body fat rebound and its preparation method and application. The composition comprises the following components in parts by weight: 0.5-10 parts of plankton extract, 0.1-1 part of Irisin, 2-5 parts lotus (Nelumbonucifera) leaf extract, 1-6 parts caffeine, 1-4 parts hydrolyzed red algae extract, and 0.01-0.1 parts oligopeptide-1. The present invention mainly uses irisin, plankton extract and functional peptide as the core compatibility to induce energy-storing white adipocytes to transform into energy-consuming brown adipocytes, prevent fat from re-accumulating in the process of reducing fat and slimming, and reduce fat loss. After the rebound phenomenon, promote positive energy consumption, so as to achieve the purpose of efficient and healthy slimming. At the same time, the biological preparation of the present invention has a synergistic effect on sports slimming.

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.

This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of PRDM16(P) and C / EBPβ(C), the reprogramming-related gene being at least one member selected from the group consisting of Myc family genes (c-Myc(M), N-Myc, L-Myc(L), S-Myc, and B-Myc), GLIS family genes (GLIS1 (G), GLIS 2, and GLIS 3), Klf family genes (KLF1, KLF2, KLF3, KLF4(K), KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16, and KLF17), Oct family genes, Sox family genes, and Lin-28.

The present invention provides new applications of miR-327 inhibitors and / or FGF10 promoters, especially the applications in the preparation of drugs for preventing and / or treating diabetes. miR-327 inhibitors and FGF10 promoters can both promote the increase of FGF10 in the stromal cell components of adipose tissue, promote the differentiation of stromal cell component adipocyte precursors into brown adipocytes, increase energy consumption, and promote fat metabolism, thereby preventing And / or the effect of treating lipodystrophy. The present invention also provides a drug for preventing and / or treating lipodystrophy, including miR‑327 inhibitor and a pharmaceutically acceptable carrier thereof.

Use of a transforming growth factor beta (TGF-β) signalling inhibitor for producing a population of brown adipocytes in vitro.

Use of a transforming growth factor beta (TGF-Beta) signalling inhibitor for producing a population of brown adipocytes in vitro is described.

The present invention provides an application of human brown adipocyte-secreted peptide FAQPEILIGTIPGAGGTQR in the prevention and treatment of obesity; brown adipocyte-secreted peptide FAQPEILIGTIPGAGGTQR can achieve weight loss effect in obese model mice, and improve insulin sensitivity and glucose tolerance, and play a role in the prevention and treatment of obesity. At the same time, FAQPEILIGTIPGAGGTQR can also slow down the weight gain caused by high-fat diet under mild cold exposure, reduce blood sugar, blood lipid and other obesity-related abnormal metabolic indicators, and play a role in preventing obesity; therefore, the brown adipocytes secrete peptide The derivatives and drug combinations thereof have the potential to prepare polypeptide drugs for treating and preventing obesity and its complications.

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.

The invention discloses a method for constructing a genetically engineered cell line of anti-obesity drug target UCP1, and at the same time discloses the establishment and application of a high-throughput screening model for anti-obesity drugs. It mainly involves using the CRISPR / Cas9 system to design two unique sgRNAs to knock in luciferase‑T2A‑tdTomato‑WPRE‑pA after the N-terminal ATG of the UCP1 gene in cells, especially knocking luciferase and tdTomato into immortalized brown adipocyte UCP1 The first stably transfected brown adipocyte cell line with luciferase and tdTomato inserted into the UCP1 promoter region was formed, and it was used in high-throughput screening of anti-obesity drugs, evaluation of anti-obesity drugs, and anti-obesity active substances in the body. evaluation and development of UCP1 detection kits. UCP1 is an uncoupling protein specifically expressed in brown adipose tissue and a new target for anti-obesity. The construction of this stable transgenic engineered cell line is suitable for the application of reporter genes and high-content methods, sensitive, accurate and efficient. Through flux screening, it is of great significance to obtain anti-obesity drugs that promote thermogenesis and reduce body weight.